[1]
|
石宇, 季斌, 赵洪瑜, 等. 顺铂联合多西他赛同步放化疗对局部晚期食管胃交界癌患者生存质量的影响[J]. 江苏医药, 2017, 43(20): 1476-1479.
|
[2]
|
Du, K.P., Huang, W.P., Liu, S.Y., et al. (2022) Application of Computed Tomography-Based Radiomics in Differential Diagnosis of Adenocarcinoma and Squamous Cell Carcinoma at the Esophagogastric Junction. World Journal of Gastroenterology, 28, 4363-4375. https://doi.org/10.3748/wjg.v28.i31.4363
|
[3]
|
Yamashita, H. and Seto, Y. (2015) Optimal Surgical Approach for Esophagogastric Junction Carcinoma. Nihon Geka Gakkai Zasshi, 116, 40-44.
|
[4]
|
Kalish, R.J., Clancy, P.E., Orringer, M.B., et al. (1984) Clinical, Epidemiologic, and Morphologic Comparison between Adenocarcinomas Arising in Barrett’s Esophageal Mucosa and in the Gastric Cardia. Gastroenterology, 86, 461-467. https://doi.org/10.1016/S0016-5085(84)80016-5
|
[5]
|
Kurokawa, Y., Sasako, M. and Doki, Y. (2013) Treatment Approaches to Esophagogastric Junction Tumors. Digestive Surgery, 30, 169-173. https://doi.org/10.1159/000350880
|
[6]
|
Fang, W.L., Wu, C.W., Chen, J.H., et al. (2009) Esophagogastric Junction Adenocarcinoma According to Siewert Classification in Taiwan. Annals of Surgical Oncology, 16, 3237-3244. https://doi.org/10.1245/s10434-009-0636-9
|
[7]
|
Okabayashi, T., Gotoda, T., Kondo, H., et al. (2000) Early Carcinoma of the Gastric Cardia in Japan: Is It Different from That in the West? Cancer, 89, 2555-2559. https://doi.org/10.1002/1097-0142(20001215)89:12<2555::AID-CNCR6>3.0.CO;2-R
|
[8]
|
Lagergren, J., Bergstrom, R., Lindgren, A., et al. (1999) Symptomatic Gastroesophageal Reflux as a Risk Factor for Esophageal Adenocarcinoma. The New England Journal of Medicine, 340, 825-831. https://doi.org/10.1056/NEJM199903183401101
|
[9]
|
Keeney, S. and Bauer, T.L. (2006) Epidemiology of Adenocarcinoma of the Esophagogastric Junction. Surgical Oncology Clinics of North America, 15, 687-696. https://doi.org/10.1016/j.soc.2006.07.014
|
[10]
|
Yamashita, H., Seto, Y., Sano, T., et al. (2017) Results of a Nation-Wide Retrospective Study of Lymphadenectomy for Esophagogastric Junction Carcinoma. Gastric Cancer, 20, 69-83. https://doi.org/10.1007/s10120-016-0663-8
|
[11]
|
Huang, Q., Fan, X., Agoston, A.T., et al. (2011) Comparison of Gastro-Oesophageal Junction Carcinomas in Chinese versus American Patients. Histopathology, 59, 188-197. https://doi.org/10.1111/j.1365-2559.2011.03924.x
|
[12]
|
Huang, Q. (2012) Carcinoma of the Gastroesophageal Junction in Chinese Patients. World Journal of Gastroenterology, 18, 7134-7140. https://doi.org/10.3748/wjg.v18.i48.7134
|
[13]
|
Haggitt, R.C. (1994) Barrett’s Esophagus, Dysplasia, and Adenocarcinoma. Human Pathology, 25, 982-993. https://doi.org/10.1016/0046-8177(94)90057-4
|
[14]
|
Cameron, A.J., Souto, E.O. and Smyrk, T.C. (2002) Small Adenocarcinomas of the Esophagogastric Junction: Association with Intestinal Metaplasia and Dysplasia. American Journal of Gastroenterology, 97, 1375-1380. https://doi.org/10.1111/j.1572-0241.2002.05669.x
|
[15]
|
刘舒颖. 食管胃交界癌107例内镜下诊断及病理分析[J]. 中国医学工程, 2015, 23(4): 170-171.
|
[16]
|
Chevallay, M., Bollschweiler, E., Chandramohan, S.M., et al. (2018) Cancer of the Gastroesophageal Junction: A Diagnosis, Classification, and Management Review. Annals of the New York Academy of Sciences, 1434, 132-138. https://doi.org/10.1111/nyas.13954
|
[17]
|
王伟. 食管胃交界癌的诊疗现状及争议[D]: [硕士学位论文]. 石家庄: 河北医科大学, 2017.
|
[18]
|
Jung, M.K., Schmidt, T., Chon, S.H., et al. (2020) Current Surgical Treatment Standards for Esophageal and Esophagogastric Junction Cancer. Annals of the New York Academy of Sciences, 1482, 77-84. https://doi.org/10.1111/nyas.14454
|
[19]
|
Haverkamp, L., Ruurda, J.P., Van Leeuwen, M.S., et al. (2014) Systematic Review of the Surgical Strategies of Adenocarcinomas of the Gastroesophageal Junction. Surgical Oncology, 23, 222-228. https://doi.org/10.1016/j.suronc.2014.10.004
|
[20]
|
Blank, S., Schmidt, T., Heger, P., et al. (2018) Surgical Strategies in True Adenocarcinoma of the Esophagogastric Junction (AEG II): Thoracoabdominal or Abdominal Approach? Gastric Cancer, 21, 303-314. https://doi.org/10.1007/s10120-017-0746-1
|
[21]
|
Bechev, B., Magunska, N., Ivanov, S., et al. (2015) Laparoscopic Sacrocolpopexy. Akuserstvo i Ginekologija (Sofiia), 54, 28-32.
|
[22]
|
Hulscher, J.B., Van Sandick, J.W., De Boer, A.G., et al. (2002) Extended Transthoracic Resection Compared with Limited Transhiatal Resection for Adenocarcinoma of the Esophagus. The New England Journal of Medicine, 347, 1662-1669. https://doi.org/10.1056/NEJMoa022343
|
[23]
|
Omloo, J.M., Lagarde, S.M., Hulscher, J.B., et al. (2007) Extended Transthoracic Resection Compared with Limited Transhiatal Resection for Adenocarcinoma of the Mid/Distal Esophagus: Five-Year Survival of a Randomized Clinical Trial. Annals of Surgery, 246, 992-1001. https://doi.org/10.1097/SLA.0b013e31815c4037
|
[24]
|
Sasako, M., Sano, T., Yamamoto, S., et al. (2006) Left Thoracoabdominal Approach versus Abdominal-Transhiatal Approach for Gastric Cancer of the Cardia or Subcardia: A Randomised Controlled Trial. The Lancet Oncology, 7, 644-651. https://doi.org/10.1016/S1470-2045(06)70766-5
|
[25]
|
Wei, M.T., Zhang, Y.C., Deng, X.B., et al. (2014) Transthoracic vs Transhiatal Surgery for Cancer of the Esophagogastric Junction: A Meta-Analysis. World Journal of Gastroenterology, 20, 10183-10192. https://doi.org/10.3748/wjg.v20.i29.10183
|
[26]
|
Orditura, M., Galizia, G., Fabozzi, A., et al. (2013) Preoperative Treatment of Locally Advanced Esophageal Carcinoma (Review). International Journal of Oncology, 43, 1745-1753. https://doi.org/10.3892/ijo.2013.2118
|
[27]
|
Orditura, M., Galizia, G., Sforza, V., et al. (2014) Treatment of Gastric Cancer. World Journal of Gastroenterology, 20, 1635-1649. https://doi.org/10.3748/wjg.v20.i7.1635
|
[28]
|
Ronellenfitsch, U., Schwarzbach, M., Hofheinz, R., et al. (2013) Preoperative Chemo(Radio)Therapy versus Primary Surgery for Gastroesophageal Adenocarcinoma: Systematic Review with Meta-Analysis Combining Individual Patient and Aggregate Data. European Journal of Cancer, 49, 3149-3158. https://doi.org/10.1016/j.ejca.2013.05.029
|
[29]
|
Ychou, M., Boige, V., Pignon, J.P., et al. (2011) Perioperative Chemotherapy Compared with Surgery Alone for Resectable Gastroesophageal Adenocarcinoma: An FNCLCC and FFCD Multicenter Phase III Trial. Journal of Clinical Oncology, 29, 1715-1721. https://doi.org/10.1200/JCO.2010.33.0597
|
[30]
|
Cunningham, D., Allum, W.H., Stenning, S.P., et al. (2006) Perioperative Chemotherapy versus Surgery Alone for Resectable Gastroesophageal Cancer. The New England Journal of Medicine, 355, 11-20. https://doi.org/10.1056/NEJMoa055531
|
[31]
|
Davies, A.R., Gossage, J.A., Zylstra, J., et al. (2014) Tumor Stage after Neoadjuvant Chemotherapy Determines Survival after Surgery for Adenocarcinoma of the Esophagus and Esophagogastric Junction. Journal of Clinical Oncology, 32, 2983-2990. https://doi.org/10.1200/JCO.2014.55.9070
|
[32]
|
Van Hagen, P., Hulshof, M.C., Van, Lanschot, J.J., et al. (2012) Preoperative Chemoradiotherapy for Esophageal or Junctional Cancer. The New England Journal of Medicine, 366, 2074-2084. https://doi.org/10.1056/NEJMoa1112088
|
[33]
|
Orditura, M., Galizia, G., Di Martino, N., et al. (2014) Effect of Preoperative Chemoradiotherapy on Outcome of Patients with Locally Advanced Esophagogastric Junction Adenocarcinoma—A Pilot Study. Current Oncology, 21, 125-133. https://doi.org/10.3747/co.21.1570
|
[34]
|
Shapiro, J., Van Lanschot, J., Hulshof, M., et al. (2015) Neoadjuvant Chemoradiotherapy plus Surgery versus Surgery Alone for Oesophageal or Junctional Cancer (CROSS): Long-Term Results of a Randomised Controlled Trial. The Lancet Oncology, 16, 1090-1098. https://doi.org/10.1016/S1470-2045(15)00040-6
|
[35]
|
Blum, M.M., Xiao, L., Patel, V.R., et al. (2017) Pathological Complete Response in Patients with Esophageal Cancer after the Trimodality Approach: The Association with Baseline Variables and Survival—The University of Texas MD Anderson Cancer Center Experience. Cancer, 123, 4106-4113. https://doi.org/10.1002/cncr.30953
|
[36]
|
Lordick, F., Stein, H.J., Peschel, C., et al. (2004) Neoadjuvant Therapy for Oesophagogastric Cancer. British Journal of Surgery, 91, 540-551. https://doi.org/10.1002/bjs.4575
|
[37]
|
Siewert, J.R., Stein, H.J. and Von Rahden, B.H. (2005) Multimodal Treatment of Gastrointestinal Tract Tumors: Consequences for Surgery. World Journal of Surgery, 29, 940-948. https://doi.org/10.1007/s00268-005-0010-4
|
[38]
|
Khan, U. and Shah, M.A. (2019) Ramucirumab for the Treatment of Gastric or Gastro-Esophageal Junction Cancer. Expert Opinion on Biological Therapy, 19, 1135-1141. https://doi.org/10.1080/14712598.2019.1656715
|
[39]
|
Garon, E.B., Ciuleanu, T.E., Arrieta, O., et al. (2014) Ramucirumab plus Docetaxel versus Placebo plus Docetaxel for Second-Line Treatment of Stage IV Non-Small-Cell Lung Cancer after Disease Progression on Platinum-Based Therapy (REVEL): A Multicentre, Double-Blind, Randomised Phase 3 Trial. The Lancet, 384, 665-673. https://doi.org/10.1016/S0140-6736(14)60845-X
|
[40]
|
Fuchs, C.S., Tomasek, J., Yong, C.J., et al. (2014) Ramucirumab Monotherapy for Previously Treated Advanced Gastric or Gastro-Oesophageal Junction Adenocarcinoma (REGARD): An International, Randomised, Multicentre, Placebo-Controlled, Phase 3 Trial. The Lancet, 383, 31-39. https://doi.org/10.1016/S0140-6736(13)61719-5
|
[41]
|
Sahin, U., Tureci, O., Manikhas, G., et al. (2021) FAST: A Randomised Phase II Study of Zolbetuximab (IMAB362) plus EOX versus EOX Alone for First-Line Treatment of Advanced CLDN18.2-Positive Gastric and Gastro-Oesophageal Adenocarcinoma. Annals of Oncology, 32, 609-619. https://doi.org/10.1016/j.annonc.2021.02.005
|
[42]
|
Birla, R., Hoara, P., Caragui, A., et al. (2018) Current Management of Locally Advanced Junction Esophagogastric Adenocarcinoma. Chirurgia (Bucur), 113, 38-45. https://doi.org/10.21614/chirurgia.113.1.38
|
[43]
|
Power, D.G. and Reynolds, J.V. (2010) Localized Adenocarcinoma of the Esophagogastric Junction—Is There a Standard of Care? Cancer Treatment Reviews, 36, 400-409. https://doi.org/10.1016/j.ctrv.2010.01.001
|